摘要
目的探索不同剂量的瑞舒伐他汀治疗急性ST 段抬高型心肌梗死的疗效。方法在我院2016 年3 月-2018 年2 月收治的急性ST 段抬高型心肌梗死患者中选出159 例为研究对象,全部患者均接受急诊PCI 术治疗,在术前术后给予瑞舒伐他汀治疗,根据用药剂量分为高剂量组(20 mg/d)、中剂量组(10 mg/d)和低剂量组(5 mg/d),比较三组患者的围手术期指标。结果生化指标CRP、IL-6、CK-MB、BNP、cTn-Ⅰ比较:与PCI 术前相比,PCI 术后24h 三组患者的指标值均有明显升高,但是高剂量组的升高幅度最低,明显低于其余两组,P < 0.05;而中剂量组与低剂量组比较差异无统计学意义,P > 0.05。随访1 个月的心血管事件发生率对比:高剂量组为5.66%,中剂量组为18.87%,低剂量组为22.64%,三组比较差异有统计学意义(P < 0.05);药物不良反应发生率三组对比差异差异无统计学意义(P > 0.05)。结论 20 mg/d 瑞舒伐他汀在急性ST 段抬高型心肌梗死患者治疗中应用效果确切,有助于减轻PCI 围术期的炎症反应、心肌损伤,减少不良心血管事件发生,改善预后。
Objective To explore the efficacy of different doses of rosuvastatin in the treatment of acute ST-segment elevation myocardial infarction. Methods 159 patients with acute ST-segment elevation myocardial infarction were selected from our hospital from March 2016 to February 2018. All patients were treated with emergency PCI and rosuvastatin before and after operation. According to the dosage group, high dose group (20 mg/d), middle dose group (10 mg/d) and low dose group (5 mg/d), comparison of three groups of patients with perioperative indicators. Results Biochemical index CRP, IL-6, CK-MB, BNP, cTn-Ⅰ contrast: compared with the preoperative PCI, PCI postoperative 24 h index of three groups of patients were increased significantly, but high dose group of the rise of the lowest, significantly lower than the rest of the two groups, P < 0.05;The middle dose group and low dose group of comparison difference is not obvious, P > 0.05. The incidence of cardiovascular events at 1 month follow-up was 5.66% in the high-dose group, 18.87% in the middle-dose group, and 22.64% in the low-dose group, P<0.05. There was no significant difference in the incidence of adverse drug reactions among the three groups, P > 0.05. Conclusion 20 mg/d rosuvastatin is effective in the treatment of acute ST-segment elevation myocardial infarction. It can help to reduce perioperative inflammation and myocardial injury, reduce adverse cardiovascular events and improve prognosis of patients with acute ST-segment elevation myocardial infarction.
作者
赵丹
ZHAO Dan(Department of Cardiology, Inner Mongolia Forestry General Hospital, Yakeshi Inner Mongolia 022150, China)
出处
《中国继续医学教育》
2019年第25期143-145,共3页
China Continuing Medical Education
关键词
瑞舒伐他汀
急性ST段抬高型心肌梗死
PCI介入疗法
剂量
炎症反应
心功能
rosuvastatin
acute ST-segment elevation myocardial infarction
PCI interventional therapy
dose
Inflammatory response
Cardiac function
